RYBREVANT (amivantamab-vmjw)
ANTINEOPLASTIC - BISPECIFIC EGFR AND MET REC INHIBITOR MC AB · NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION ·+2
JANSSEN BIOTECH, Inc.
Drug class
Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab
"Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab" is a pharmacotherapeutic and compendial formulary class designation for bispecific monoclonal antibodies directed against epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). Read more about Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab
2 drugs in this class 1 manufacturers
Drugs in Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab
RYBREVANT FASPRO (amivantamab-hyaluronidase, human recombinant-lpuj)
HYALURONIDASE ENZYMES · NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION ·+2
JANSSEN BIOTECH, Inc.
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab preselected. Add indication or manufacturer filters there.
"Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab" is a pharmacotherapeutic and compendial formulary class designation for bispecific monoclonal antibodies directed against epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET).
Agents in this class, notably amivantamab, exert their antineoplastic effect by simultaneously binding the extracellular domains of EGFR and MET, thereby blocking ligand engagement, promoting receptor degradation, and engaging immune effector mechanisms such as antibody-dependent cellular cytotoxicity.
Their primary therapeutic role is in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring specific genetic alterations, such as EGFR exon 20 insertion mutations or classical EGFR-sensitizing mutations.
-
proquest.com
"Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab" is a pharmacotherapeutic and compendial formulary class designation for bispecific monoclonal antibodies directed against epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) Agents in this class, notably amivantamab, exert their antineoplastic effect by simultaneously binding the extracellular domains of EGFR and MET, thereby blocking ligand engagement, promoting receptor degradation, and engagi...
-
sfhp.org
"Antineoplastic - Bispecific EGFR and MET Rec Inhibitor MC Ab" is a pharmacotherapeutic and compendial formulary class designation for bispecific monoclonal antibodies directed against epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET)
-
goodrx.com
Agents in this class, notably amivantamab, exert their antineoplastic effect by simultaneously binding the extracellular domains of EGFR and MET, thereby blocking ligand engagement, promoting receptor degradation, and engaging immune effector mechanisms such as antibody-dependent cellular cytotoxicity
-
researchgate.net
Their primary therapeutic role is in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring specific genetic alterations, such as EGFR exon 20 insertion mutations or classical EGFR-sensitizing mutations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.